104075-51-6

Upstream product

• 141-97-9 ethyl acetoacetate 
• 552-45-4 1-chloromethyl-2-methylbenzene 
• 89-92-9 2-methylbenzyl bromide 

Downstream Products

• 57132-25-9 4-(2-methylphenyl)butan-2-one 
• 1091602-23-1 C₁₈H₂₁N₃O₄S 
• 1263575-78-5 5-methyl-4-(2-methylbenzyl)-2-phenyl-3,4-dihydro-2H-pyrazol-3-one 
• 161461-12-7 ethyl 2-chloro-2-(o-methylbenzyl)-acetoacetate 
• 127459-68-1 7-(2-methylphenyl)-2,5-dimethylhept-3-yne-2,5-diol 
• 127459-69-2 7-(2-methylphenyl)-2,5-dimethylheptane-2,5-diol 

Relevant academic research and scientific papers

Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor

We optimized the structure of an active metabolite (1) of WAY-123783, which was obtained from mouse urine after oral administration, to improve selectivity for SGLT2 and oral bioavailability. O-glucoside derivative 24 (remogliflozin etabonate) was subsequently identified as a potent, highly selective, and orally available SGLT2 inhibitor.

Tunable Aerobic Oxidative Hydroxylation/Dehydrogenative Homocoupling of Pyrazol-5-ones under Transition-Metal-Free Conditions

A practical and tunable transition-metal-free aerobic oxidation of pyrazol-5-ones preparing either 4-hydroxypyrazoles (via C-H hydroxylation) or bispyrazoles (via dehydrogenative homocoupling) is described. The K2CO3/dioxane reagent system predominately promoted hydroxylation to deliver the α-hydroxylated pyrazoles. In contrast, the formation of bispyrazoles was overwhelmingly preferred with CH3CN as the reaction medium without any additives.

Carbonic anhydrase inhibitors: Synthesis and inhibition studies against mammalian isoforms I-XV with a series of 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides

A series of 2-(hydrazinocarbonyl)-3-substitutedphenyl-1H-indole-5-sulfonamides possessing various 2-, 3- or 4- substituted phenyl groups with methyl-, halogeno- and methoxy- functionalities, as well as the perfluorophenyl moiety have been synthesized and

2-OXO-2H-CHROMENE COMPOUNDS

Compounds of structural formula (1) modulate CRTH2 activity and are of utility in, for example, respiratory diseases formula (1): in which: A represents a direct bond, an optionally substituted alkylene or alkenylene group, or a group of formula Z-(optionally substituted)alkylene; B represents a direct bond, an optionally substituted alkylene or alkenylene group, or a group of formula Z-(optionally substituted)alkylene or (optionally substituted)alkylene-Z; Z represents an oxygen atom, an NH or N-alkyl group, or a group of formula S(O)n, in which n = 0 to 2; X represents a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, sulfonic acid or a group of formula C(=O)NHSO2W or SO2NHC(=O)W; W represents an optionally substituted aryl or heteroaryl group or an optionally substituted alkyl or cycloalkyl group; Y represents an optionally substituted phenyl or 5- or 6-membered heteroaryl group, Ra, Rb, and Rc independently represent hydrogen, acyl, alkoxy, alkoxycarbonyl, alkylamino, alkylsulfinyl, alkylsulfonyl, alkylthio, -NH2, aminoalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, cyano, dialkylamino, halo, haloalkoxy, haloalkyl, alkyl, alkenyl, -OH, optionally substituted aryl, optionally substituted heteroaryl, heterocycloalkyl, aminoacyl, aminosulfonyl, acylamino, sulfonylamino, heteroarylalkyl, cyclic amino, aryloxy, heteroaryloxy, arylalkyloxy or heteroarylalkyloxy.

Phenylethl o-methylcinnamate, a process for preparation and a fragrance composition containing same

The invention relates to phenylethyl o-methylcinnamate and a process for its preparation. Phenylethyl o-methylcinnamate is prepared by, first, alkylating ethyl acetoacetate with o-methylbenzyl chloride in the presence of a phase transfer catalyst to yield 2-(o-methylbenzyl)-acetoacetate. Thereafter the 2-(o-methylbenzyl)-acetoacetate yielded in the alkylating step is halogenated to yield ethyl 2-halo-2-(o-methylbenzyl)-acetoacetate. This is followed by degarding the ethyl 2-halo-2-(o-methylbenzyl)-acetoacetate acid. Finally the o-methylcinnamic acid obtained in the degarding step is esterified with 2-phenylethanol into phenylethyl o-methylcinnamate. A fragrance composition utilizing phenylethyl o-methylcinnamate is also disclosed.

New Aromatic Musk Odorants: Design and Synthesis

By appropriate structural modification of known musk odorants, new strong musk odorants have been discovered.Incorporation of supplementary CH3 or CH2 groups into the basic musk skeleton of type G only slightly modifies the global shape of the molecule but leads to densely packed structures of enhanced lipophilicity.For the consturction of these highly substituted 1,2,3,4-tetrahydrohaphthalenes, new annulation sequences (intramolecular mono- and dialkylations; see Schemes 3, 6, and 8) have been developed and, in certain cases, the design of the target molecules was dictated by both structure-activity-realationship and synthetic considerations (e. g. 46 and 47, Scheme 6).This work also presents an original solution to an analytical problem: the distinction between a C2- and a Cs-symmetrical aromatic hydrocarbon (viz. 71 and 72) by conversion into a complex.

4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors

A process for the preparation of a substituted imidazole of the formula STR1 wherein X is --CH 2 --, --CH 2 CH 2 -- or --O-- R 1 is H, lower alkyl or lower alkenyl, OCH 3 or OCH 2 CH 3, R 2 is H, CH 3, CH 2 CH 3, OCH 3 or OH, R 3 is H, CH 3, CH 2 CH 3, OCH 3 or Hal, R 4 is H, CH 3, CH 2 CH 3, OCH 3 or Hal, and Hal is halogen and their non-toxic acid addition salts exhibit valuable pharmacological activity and are useful especially as selective α 2 -receptor antagonists.